Neumax

Neumax is an oral, immediate-release formulation of levofloxacin (750 mg) developed by Gebro Pharma. It is approved for the treatment of community-acquired pneumonia (CAP) in adults. As a fluoroquinolone antibiotic, levofloxacin exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and DNA topoisomerase IV, which are essential for bacterial DNA replication, transcription, repair, and recombination. This inhibition leads to double-stranded DNA breaks and rapid bacterial cell death. Neumax offers a high-dose, short-course treatment regimen (750 mg once daily for 5 days) designed to optimize efficacy and patient compliance in managing CAP.

Brand names

Neumax

Other names

levofloxacin 750 mglevofloxacin750 mglevofloxacin-750 mglevofloxacin hemihydrate 750 mg